| Barriers | Enablers |
---|---|---|
Patient-level | Low motivation to engage with the treatment Difficulty in processing diagnosis-related information Competing priorities | Patient education sessions delivered by trained RHN both prior to, and as required throughout, treatment |
Provider-level | Low confidence in identifying and responding to adverse reactions caused by LTBI medication | Participation in high quality primary care provider education sessions Ongoing support from MHRHW infectious diseases physicians Co-design and established relationships with infectious diseases physicians Familiarity with cultural and clinical aspects relevant to the refugee patient group Multilingual proficiency and interpreter access |
Organisational-level | Operational limitations including: Limited time for patient education and follow-up Lack of workforce to coordinate patient education and follow-up Limited financial resources | Extensive involvement of MHRHW RHN in patient follow-up Extended GP consultations Designated resources and time to support patient education and clinical follow-up Resources to proactively contact patients who fail to attend appointments or pick up medication |
Clinical-level | Available treatment barriers: Adverse reactions Length of treatment | Free access to medication |